The current status of prophylactic replacement therapy in children and adults with haemophilia

British Journal of Haematology

Volumn 169, Issue 6, 2015, Pages 777-786

  Ljung, Rolf ^a,b   Gretenkort Andersson, Nadine ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor IX; Factor VIII; Haemophilia A; Haemophilia B; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ADULT; AGE; AGING; CHILD CARE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; LONG TERM CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SUBSTITUTION THERAPY; TREATMENT PLANNING; VASCULAR ACCESS; CHILD; COMPLICATION; HEMORRHAGE; PREMEDICATION;

ADULT; AGE FACTORS; CHILD; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; PREMEDICATION;

EID: 84930268161     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13365     Document Type: Review

References (79)

1. Ahlberg, A. (1965) Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica Scandinavica. Supplementum, 77, 3-132.
2. Aledort, L.M., Haschmeyer, R.H. & Pettersson, H. (1994) A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. Journal of Internal Medicine, 236, 391-399.
3. Astermark, J., Petrini, P., Tengborn, L., Schulman, S., Ljung, R. & Berntorp, E. (1999) Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. British Journal of Haematology, 105, 1109-1113.
4. Auerswald, G., Bidlingmaier, C. & Kurnik, K. (2012) Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia, 18, e18-e20.
5. Berntorp, E., Boulyjenkov, V., Brettler, D., Chandy, M., Jones, P., Lee, C., Lusher, J., Mannucci, P., Peake, I. & Rickard, K. (1995) Modern treatment of haemophilia. Bulletin of the World Health Organization, 73, 691-701.
6. Björkman, S. (2013) Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia, 19, 753-757.
7. Björkman, S., Folkesson, A. & Jönsson, S. (2009) Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. European Journal of Clinical Pharmacology, 65, 989-998.
8. Björkman, S., Oh, M., Spotts, G., Schroth, P., Fritsch, S., Ewenstein, B.M., Casey, K., Fischer, K., Blanchette, V.S. & Collins, P.W. (2012) Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood, 119, 612-618.
9. Blanchette, V.S., Key, N.S., Ljung, L.R., Manco-Johnson, M.J., van den Berg, H.M. & Srivastava, A.; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. (2014) Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 12, 1935-1939.
10. Broderick, C.R., Herbert, R.D., Latimer, J., Barnes, C., Curtin, J.A., Mathieu, E., Monagle, P. & Brown, S.A. (2012a) Association between physical activity and risk of bleeding in children with hemophilia. Journal of the American Medical Association, 308, 1452-1459.
11. Broderick, C.R., Herbert, R.D., Latimer, J., Mathieu, E., van Doorn, N. & Curtin, J.A. (2012b) Feasibility of short message service to document bleeding episodes in children with haemophilia. Haemophilia, 18, 906-910.
12. Calvez, T., Chambost, H., Claeyssens-Donadel, S., d'Oiron, R., Goulet, V., Guillet, B., Héritier, V., Milien, V., Rothschild, C., Roussel-Robert, V., Vinciguerra, C. & Goudemand, J.; FranceCoag Network. (2014) Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood, 124, 3398-3408.
13. Carlsson, M., Berntorp, E., Björkman, S., Lethagen, S. & Ljung, R. (1997) Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia, 3, 96-101.
14. Clausen, N., Petrini, P., Claeyssens-Donadel, S., Gouw, S.C. & Liesner, R.; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. (2014) Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia, 20, 747-755.
15. Collins, P.W., Blanchette, V.S., Fischer, K., Björkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J. & Ewenstein, B.; rAHF-PFM Study Group. (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 7, 413-420.
16. Collins, P.W., Björkman, S., Fischer, K., Blanchette, V., Oh, M., Schroth, P., Fritsch, S., Casey, K., Spotts, G. & Ewenstein, B.M. (2010) Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostasis, 8, 269-275.
17. Collins, P.W., Fischer, K., Morfini, M., Blanchette, V.S. & Björkman, S.; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. (2011) Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 17, 2-10.
18. Collins, P.W., Palmer, B.P., Chalmers, E.A., Hart, D.P., Liesner, R., Rangarajan, S., Talks, K., Williams, M. & Hay, C.R.; UK Haemophilia Centre Doctors' Organization. (2014) Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 124, 3389-3397.
19. Coppola, A., Santoro, C., Franchini, M., Mannucci, C., Mogavero, S., Molinari, A.C., Schinco, P., Tagliaferri, A. & Santoro, R.C. (2013) Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities. Seminars in Thrombosis and Hemostasis, 39, 794-802.
20. Coyle, T.E., Reding, M.T., Lin, J.C., Michaels, L.A., Shah, A. & Powell, J. (2014) Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. Journal of Thrombosis and Haemostasis, 12, 488-496.
21. Darby, S.C., Kan, S.W., Spooner, R.J., Giangrande, P.L., Hill, F.G., Hay, C.R., Lee, C.A., Ludlam, C.A. & Williams, M. (2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood, 110, 815-825.
22. Di Minno, G., Canaro, M., Ironside, J.W., Navarro, D., Perno, C.F., Tiede, A. & Gürtler, L. (2013) Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica, 98, 1495-1498.
23. van Dijk, K., Fischer, K., van der Bom, J.G., Scheibel, E., Ingerslev, J. & van den Berg, H.M. (2005) Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. British Journal of Haematology, 130, 107-112.
24. Feldman, B.M., Pai, M., Rivard, G.E., Israels, S., Poon, M.C., Demers, C., Robinson, S., Luke, K.H., Wu, J.K., Gill, K., Lillicrap, D., Babyn, P., McLimont, M. & Blanchette, V.S.; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. (2006) Tailored prophylaxis in severe haemophilia A: interim results from the first 5 year of the Canadian Hemophilia Primary Prophylaxis Study. Journal of Thrombosis and Haemostasis, 4, 1228-1236.
25. Fischer, K., Van Der Bom, J.G., Prejs, R., Mauser-Bunschoten, E.P., Roosendaal, G., Grobbee, D.E. & Van Den Berg, H.M. (2001) Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia, 7, 544-550.
26. Fischer, K., Steen Carlsson, K., Petrini, P., Holmström, M., Ljung, R., van den Berg, H.M. & Berntorp, E. (2013) Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 122, 1129-1136.
27. Giangrande, P., Seitz, R., Behr-Gross, M.E., Berger, K., Hilger, A., Klein, H., Schramm, W. & Mannucci, P.M. (2014a) Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 20, 322-325.
28. Giangrande, P., Calizzani, G., Menichini, I., Candura, F., Mannucci, P.M. & Makris, M. (2014b) The European standards of Haemophilia Centres. Blood Transfusion, 12, S525-S530.
29. Gomez, K., Klamroth, R., Mahlangu, J., Mancuso, M.E., Mingot, M.E. & Ozelo, M.C. (2014) Key issues in inhibitor management in patients with haemophilia. Blood Transfusion, 12, S319-S329.
30. Gouw, S.C., van der Bom, J.G. & van den Berg, M.H. (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109, 4648-4654.
31. Gouw, S.C., van den Berg, H.M., Fischer, K., Auerswald, G., Carcao, M., Chalmers, E., Chambost, H., Kurnik, K., Liesner, R., Petrini, P., Platokouki, H., Altisent, C., Oldenburg, J., Nolan, B., Garrido, R.P., Mancuso, M.E., Rafowicz, A., Williams, M., Clausen, N., Middelburg, R.A., Ljung, R. & van der Bom, J.G.; PedNet and Research Of Determinants of INhibitor development (RODIN) Study Group. (2013a) Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 121, 4046-4055.
32. Gouw, S.C., van der Bom, J.G., Ljung, R., Escuriola, C., Cid, A.R., Claeyssens-Donadel, S., van Geet, C., Kenet, G., Mäkipernaa, A., Molinari, A.C., Muntean, W., Kobelt, R., Rivard, G., Santagostino, E., Thomas, A. & van den Berg, H.M.; PedNet and RODIN Study Group. (2013b) Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine, 368, 231-239.
33. Graham, A. & Jaworski, K. (2014) Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia, 20, 226-229.
34. Hilliard, P., Zourikian, N., Blanchette, V., Chan, A., Elliott, B., Israels, S.J., Nilson, J., Poon, M.C., Laferriere, N., Van Neste, C., Jarock, C., Wu, J., McLimont, M. & Feldman, B. (2013) Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. Journal of Thrombosis and Haemostasis, 11, 460-466.
35. Iorio, A., Halimeh, S., Holzhauer, S., Goldenberg, N., Marchesini, E., Marcucci, M., Young, G., Bidlingmaier, C., Brandao, L.R., Ettingshausen, C.E., Gringeri, A., Kenet, G., Knöfler, R., Kreuz, W., Kurnik, K., Manner, D., Santagostino, E., Mannucci, P.M. & Nowak-Göttl, U. (2010) Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis, 8, 1256-1265.
36. Iorio, A., Marchesini, E., Marcucci, M., Stobart, K. & Chan, A.K. (2011) Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. The Cochrane Database of Systematic Reviews, Sep 7(9), CD003429.
37. Key, N.S. & Négrier, C. (2007) Coagulation factor concentrates: past, present, and future. Lancet, 370, 439-448.
38. Khair, K. (2014) Compliance, concordance and adherence: what are we talking about? Haemophilia, 20, 601-603.
39. Khawaji, M., Astermark, J. & Berntorp, E. (2012) Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. European Journal of Haematology, 88, 329-335.
40. Kraft, J., Blanchette, V., Babyn, P., Feldman, B., Cloutier, S., Israels, S., Pai, M., Rivard, G.E., Gomer, S., McLimont, M., Moineddin, R. & Doria, A.S. (2012) Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. Journal of Thrombosis and Haemostasis, 10, 2494-2502.
41. Kreuz, W., Escuriola-Ettingshausen, C., Funk, M., Schmidt, H. & Kornhuber, B. (1998) When should prophylactic treatment in patients with haemophilia A and B start?-The German experience. Haemophilia, 4, 413-417.
42. Kurnik, K., Auerswald, G. & Kreuz, W. (2014) Inhibitors and prophylaxis in paediatric haemophilia patients: focus on the German experience. Thrombosis Research, 134(Suppl. 1), S27-S32.
43. Lindvall, K., Colstrup, L., Wollter, I.M., Klemenz, G., Loogna, K., Grönhaug, S. & Thykjaer, H. (2006) Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia, 12, 47-51.
44. Lindvall, K., Astermark, J., Björkman, S., Ljung, R., Carlsson, K.S., Persson, S. & Berntorp, E. (2012) Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia, 18, 855-859.
45. Ljung, R. (2007) The risk associated with indwelling catheters in children with haemophilia. British Journal of Haematology, 138, 580-586.
46. Ljung, R.C. (2008) Intracranial haemorrhage in haemophilia A and B. British Journal of Haematology, 140, 378-384.
47. Löfqvist, T., Nilsson, I.M., Berntorp, E. & Pettersson, H. (1997) Haemophilia prophylaxis in young patients - a long-term follow-up. Journal of Internal Medicine, 24, 395-400.
48. Lundin, B., Ljung, R. & Pettersson, H.; European Paediatric Network for Haemophilia Management (PEDNET). (2005) MRI scores of ankle joints in children with haemophilia - comparison with clinical data. Haemophilia, 11, 116-122.
49. Maclean, P.S., Richards, M., Williams, M., Collins, P., Liesner, R., Keeling, D.M., Yee, T., Will, A.M., Young, D. & Chalmers, E.A.; Paediatric Working Party of UKHCDO. (2011) Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia, 17, 282-287.
50. Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. & Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine, 357, 535-544.
51. Manco-Johnson, M.J., Kempton, C.L., Reding, M.T., Lissitchkov, T., Goranov, S., Gercheva, L., Rusen, L., Ghinea, M., Uscatescu, V., Rescia, V. & Hong, W. (2013a) Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis, 11, 1119-1127.
52. Manco-Johnson, M.J., Sanders, J., Ewing, N., Rodriguez, N., Tarantino, M. & Humphries, T.; TEEN/TWEN Study Group. (2013b) Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia, 19, 727-735.
53. Mannucci, P.M. (2010) Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfusion, 8, 288-291.
54. Mannucci, P.M. & Franchini, M. (2013) Is haemophilia B less severe than haemophilia A? Haemophilia, 19, 499-502.
55. Mannucci, P.M., Gringeri, A., Peyvandi, F. & Santagostino, E. (2007) Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia, 13, 65-68.
56. Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J.M., Subramanyam, B., Fournel, M.A., Pierce, G.F. & Murphy, J.E. (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood, 116, 270-279.
57. Morado, M., Villar, A., Jiménez Yuste, V., Quintana, M. & Hernandez Navarro, F. (2005) Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia, 11, 79-83.
58. Négrier, C., Knobe, K., Tiede, A., Giangrande, P. & Moss, J. (2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood, 118, 2695-2701.
59. Nilsson, I.M., Berntorp, E., Löfqvist, T. & Pettersson, H. (1992) Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. Journal of Internal Medicine, 232, 25-32.
60. Oldenburg, J. & Albert, T. (2014) Novel products for haemostasis - current status. Haemophilia, 20, 23-28.
61. Oldenburg, J., Zimmermann, R., Katsarou, O., Theodossiades, G., Zanon, E., Niemann, B., Kellermann, E. & Lundin, B.; Cross-sectional MRI study investigators. (2014) Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia, doi:10.1111/hae.12539 [Epub ahead of print].
62. Pettersson, H., Ahlberg, A. & Nilsson, I.M. (1980) A radiologic classification of hemophilic arthropathy. Clinical Orthopaedics and Related Research, 149, 153-159.
63. Powell, J.S., Pasi, K.J., Ragni, M.V., Ozelo, M.C., Valentino, L.A., Mahlangu, J.N., Josephson, N.C., Perry, D., Manco-Johnson, M.J., Apte, S., Baker, R.I., Chan, G.C., Novitzky, N., Wong, R.S., Krassova, S., Allen, G., Jiang, H., Innes, A., Li, S., Cristiano, L.M., Goyal, J., Sommer, J.M., Dumont, J.A., Nugent, K., Vigliani, G., Brennan, A., Luk, A. & Pierce, G.F.; B-LONG Investigators. (2013) Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New England Journal of Medicine, 369, 2313-2323.
64. Powell, J., Shapiro, A., Ragni, M., Negrier, C., Windyga, J., Ozelo, M., Pasi, J., Baker, R., Potts, J., Li, S., Mei, B., Pierce, G.F. & Robinson, B. (2015) Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. British Journal of Haematology, 168, 113-123.
65. Ramgren, O. (1962) Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Medica Scandinavica, 171, 237-242.
66. Richards, M., Altisent, C., Batorova, A., Chambost, H., Dolan, G., de Moerloose, P., Fraga, M., Hermans, C., Karafoulidou, A., Klamroth, R., Lassila, R. & Rothschild, C. (2007) Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia, 13, 473-479.
67. Richards, M., Williams, M., Chalmers, E., Liesner, R., Collins, P., Vidler, V. & Hanley, J.; Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. (2010) A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. British Journal of Haematology, 149, 498-507.
68. Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Mazzucconi, M.G., Tagliaferri, A., Messina, M. & Mannucci, P.M. (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. British Journal of Haematology, 130, 422-427.
69. Skinner, M.W. (2012) WFH: closing the global gap - achieving optimal care. Haemophilia, 18, 1-12.
70. Soreff, J. & Blombäck, M. (1980) Arthropathy in children with severe hemophilia A. Acta Paediatrica Scandinavica, 69, 667-673.
71. Stieltjes, N., Calvez, T., Demiguel, V., Torchet, M.F., Briquel, M.E., Fressinaud, E., Claeyssens, S., Coatmelec, B. & Chambost, H.; French ICH Study Group. (2005) Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia, 11, 452-458.
72. Tagariello, G., Iorio, A., Santagostino, E., Morfini, M., Bisson, R., Innocenti, M., Mancuso, M.E., Mazzucconi, M.G., Pasta, G.L., Radossi, P., Rodorigo, G., Santoro, C., Sartori, R., Scaraggi, A., Solimeno, L.P. & Mannucci, P.M.; Italian Association Hemophilia Centre (AICE). (2009) Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood, 114, 779-784.
73. Traivaree, C., Blanchette, V., Armstrong, D., Floros, G., Stain, A.M. & Carcao, M.D. (2007) Intracranial bleeding in haemophilia beyond the neonatal period - the role of CT imaging in suspected intracranial bleeding. Haemophilia, 13, 552-559.
74. Turecek, P.L., Bossard, M.J., Graninger, M., Gritsch, H., Höllriegl, W., Kaliwoda, M., Matthiessen, P., Mitterer, A., Muchitsch, E.M., Purtscher, M., Rottensteiner, H., Schiviz, A., Schrenk, G., Siekmann, J., Varadi, K., Riley, T., Ehrlich, H.J., Schwarz, H.P. & Scheiflinger, F. (2012) BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie, 32, S29-S38.
75. Valentino, L.A., Mamonov, V., Hellmann, A., Quon, D.V., Chybicka, A., Schroth, P., Patrone, L. & Wong, W.Y.; Prophylaxis Study Group. (2012) A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis, 10, 359-367.
76. Valentino, L.A., Négrier, C., Kohla, G., Tiede, A., Liesner, R., Hart, D. & Knaub, S. (2014) The first recombinant FVIII produced in human cells - an update on its clinical development programme. Haemophilia, 20, 1-9.
77. Van Creveld, S. (1969) Prophylaxis of joint hemorrhages in haemophilia. Acta Haematologica, 41, 206-214.
78. Vermylen, J. (1998) How do some haemophiliacs develop inhibitors? Haemophilia, 4, 538-542.
79. Witmer, C., Presley, R., Kulkarni, R., Soucie, J.M., Manno, C.S. & Raffini, L. (2011) Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. British Journal of Haematology, 152, 211-216.